Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 3:11:2.
doi: 10.1186/s13098-018-0397-3. eCollection 2019.

Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis

Karla F S Melo  1   2   3 , Luciana R Bahia  2   4 , Bruna Pasinato  5 , Gustavo J M Porfirio  6 , Ana Luiza Martimbianco  6 , Rachel Riera  6   7 , Luis E P Calliari  8 , Walter J Minicucci  2 , Luiz A A Turatti  2 , Hermelinda C Pedrosa  2 , Beatriz D Schaan  5   9
Affiliations
Review

Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis

Karla F S Melo et al. Diabetol Metab Syndr. .

Abstract

Introduction: Strict glucose control using multiple doses of insulin is the standard treatment for type 1 diabetes mellitus (T1DM), but increased risk of hypoglycemia is a frequent drawback. Regular insulin in multiple doses is important for achieving strict glycemic control for T1DM, but short-acting insulin analogues may be better in reducing hypoglycemia and postprandial glucose levels.

Objective: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the effects of short-acting insulin analogues vs regular human insulin on hypoglycemia and postprandial glucose in patients with T1DM.

Methods: Searches were run on the electronic databases MEDLINE, Cochrane-CENTRAL, EMBASE, ClinicalTrials.gov, LILACS, and DARE for RCTs published until August 2017. To be included in the study, the RCTs had to cover a minimum period of 4 weeks and had to assess the effects of short-acting insulin analogues vs regular human insulin on hypoglycemia and postprandial glucose levels in patients with T1DM. Two independent reviewers extracted the data and assessed the quality of the selected studies. The primary outcomes analyzed were hypoglycemia (total episodes, nocturnal hypoglycemia, and severe hypoglycemia) and postprandial glucose (at all times, after breakfast, after lunch, and after dinner). Glycated hemoglobin (HbA1c) levels and quality of life were considered secondary outcomes. The risk of bias of each RCT was assessed using the Cochrane Collaboration Risk of Bias table, while the quality of evidence for each outcome was assessed using the GRADEpro software. The pooled mean difference in the number of hypoglycemic episodes and postprandial glucose between short-acting insulin analogues vs. regular human insulin was calculated using the random-effects model.

Results: Of the 2897 articles retrieved, 22 (6235 patients) were included. Short-acting insulin analogues were associated with a decrease in total hypoglycemic episodes (risk rate 0.93, 95% CI 0.87-0.99; 6235 patients; I2 = 81%), nocturnal hypoglycemia (risk rate 0.55, 95% CI 0.40-0.76, 1995 patients, I2 = 84%), and severe hypoglycemia (risk rate 0.68, 95% CI 0.60-0.77; 5945 patients, I2 = 0%); and with lower postprandial glucose levels (mean difference/MD - 19.44 mg/dL; 95% CI - 21.49 to - 17.39; 5031 patients, I2 = 69%) and lower HbA1c (MD - 0,13%; IC 95% - 0.16 to - 0.10; 5204 patients; I2 = 73%) levels.

Conclusions: Short-acting insulin analogues are superior to regular human insulin in T1DM patients for the following outcomes: total hypoglycemic episodes, nocturnal hypoglycemia, severe hypoglycemia, postprandial glucose, and HbA1c.

Keywords: Aspart insulin; Diabetes mellitus; Glulisine insulin; Insulin; Lispro insulin; Meta-analysis; Systematic review; Type 1 diabetes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Forest plot representing all hypoglycemic episodes (for aspart, glulisine and lispro). SAI Short-acting insulin, RHI Regular human insulin
Fig. 2
Fig. 2
Forest plot representing nocturnal hypoglycemia (for aspart, glulisine and lispro). SAI Short-acting insulin, RHI Regular human insulin
Fig. 3
Fig. 3
Forest plot representing severe hypoglycemia (for aspart, glulisine and lispro). SAI Short-acting insulin, RHI Regular human insulin
Fig. 4
Fig. 4
Forest plot representing postprandial glucose (for aspart, glulisine and lispro). SAI Short-acting insulin, RHI Regular human insulin
See this image and copyright information in PMC

References

    1. Livingstone SJ, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313(1):37–44. - PMC - PubMed
    1. Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. - PubMed
    1. Orchard TJ, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313(1):45–53. - PMC - PubMed
    1. Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes ObesMetab. 2013;15(Suppl 2):3–8. - PubMed
    1. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354(9179):617–621. - PubMed

LinkOut - more resources